[1]梁昌平,徐颖.分化型甲状腺癌患者在左甲状腺素撤药及用药状态下血清甲状腺激素、血肌酶谱和血脂的相关性分析[J].国际放射医学核医学杂志,2017,41(4):252-257.[doi:10.3760/cma.j.issn.1673-4114.2017.04.004]
 Liang Changping,Xu Ying.Relevance analysis of thyroid hormone,serum creatase enzymes and lipids in patients with differentiated thyroid cancer under and withdrawal of levothyroxine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):252-257.[doi:10.3760/cma.j.issn.1673-4114.2017.04.004]
点击复制

分化型甲状腺癌患者在左甲状腺素撤药及用药状态下血清甲状腺激素、血肌酶谱和血脂的相关性分析(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第4期
页码:
252-257
栏目:
论著
出版日期:
2017-07-25

文章信息/Info

Title:
Relevance analysis of thyroid hormone,serum creatase enzymes and lipids in patients with differentiated thyroid cancer under and withdrawal of levothyroxine treatment
作者:
梁昌平12 徐颖2
1. 671000, 大理大学医学影像学系;
2. 617000, 攀枝花市中心医院核医学科
Author(s):
Liang Changping12 Xu Ying2
1. Department of Medicine Imaging, Da Li University, Da Li 671000, China;
2. Department of Nuclear Medicine, Panzhihua Central Hospital, Panzhihua 617000, China
关键词:
甲状腺肿瘤甲状腺素血肌酶谱血脂
Keywords:
Thyroid neoplasmsThyroxineSerum creatase enzymesLipids
DOI:
10.3760/cma.j.issn.1673-4114.2017.04.004
摘要:
目的 分析分化型甲状腺癌(DTC)患者在左甲状腺素撤药及用药状态下血清甲状腺激素、血肌酶谱、血脂等指标的变化及撤药后的临床表现。方法 选取攀枝花市中心医院就诊的DTC患者46例,检测左甲状腺素撤药后4周及服用左甲状腺素后4、8、12周甲功3项[游离三碘甲腺原氨酸(FT3)、血清游离甲状腺素(FT4)、TSH]、血肌酶谱[谷草转氨酶(AST)、乳酸脱氢酶(LDH)、α-氢丁酸脱氢酶(α-HBD)、肌酸激酶(CK)、肌酸激酶同工酶(CKMB)]、血脂4项[甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)]水平,计算检验值,勾画指标随时间变化曲线图,记录患者临床症状。选取攀枝花市中心医院体检甲功正常对照者50名,行血肌酶谱、血脂4项检测。将正常对照者与DTC患者撤药后4周的血肌酶谱、血脂4项行独立样本秩和检验。DTC患者撤药后4周FT3、FT4与血肌酶谱、血脂行线性相关性分析。结果 ①DTC患者在左甲状腺素撤药后4周与正常对照者在血肌酶谱(AST、LDH、CK)、血脂4项(TG、TC、HDL、LDL)水平相比较,差异均有统计学意义,其中AST(t=3.888,P<0.05)、LDH(Z=-3.372,P<0.05)、CK(Z=-5.913,P<0.05)、TG(Z=-2.787,P<0.05)、TC(t=6.166,P<0.05)、HDL(t=3.041,P<0.05)、LDL(t=5.372,P<0.05);②DTC患者CK、TG、TC、LDL在服用左甲状腺素后4周恢复至正常范围水平;③FT3与CK、TC呈负相关,FT4与LDH、α-HBD、CK、CKMB、TG呈负相关;④左甲腺素撤药后4周DTC患者的症状以肌肉酸痛、乏力、肿胀为主要表现的占86.96%。结论 ①DTC患者撤药后可导致AST、LDH、CK、TG、TC、HDL、LDL异常;②撤药后引起血肌酶谱、血脂4项指标的变化是可逆的;③血清FT3、FT4是CK异常的影响因素;④DTC患者撤药后4周大多数发生甲减性肌病,给予左甲腺素替代治疗后症状明显缓解。
Abstract:
Objective To investigate the changes in the thyroid hormone,serum creatase enzymes,lipids,and clinical manifestations of differentiated thyroid cancer patients with levothyroxine withdrawal.Methods Forty-six differentiated thyroid carcinoma (DTC) patients were enrolled.The serial thyroid function[free triiodothyronine (FT3),free thyroxine (FT4),and thyroid stimulating hormone (TSH)],serum creatase enzymes[aspartate aminotransferase (AST),lactate dehydrogenase (LDH),alpha-hydroxybutyric dehydrogenase (α-HBD),creatine kinase (CK),and isoenzymes of creatine kinase (CKMB)],lipids[triglyceride (TG),total cholesterol (TC),high density lipoprotein (HDL),and low density lipoprotein (LDL)]levels of these patients were tested during a four-week levothyroxine withdrawal.These levels were then retested after 4,8,and 12 weeks.The time-change curve was acquired and the clinical symptoms were recorded.Fifty patients with a normal thyroid function were included in the control group.A rank-sum test and a correlation analysis were performed to analyze the relationship among the FT3,FT4,and serum creatase enzymes of patients undergoing a four-week levothyroxine withdrawal.Results ① A statistically significant relationship was observed between those patients with DTC withdrawal and those in the control group in terms of their serum creatase enzymes and lipids[AST (t=3.888,P<0.05),LDH (Z=-3.372,P<0.05),CK (Z=-5.913,P<0.05),TG (Z=-2.787,P<0.05),TC (t=6.166,P<0.05),HDL (t=3.041,P<0.05),LDL (t=5.372,P<0.05)].② CK,TG,TC,and LDL returned to their normal levels after reusing levothyroxine for four weeks.③ FT3 is negatively related to CK and TC,while FT4 is negatively related to LDH,α-HBD,CK,CKMB,and TG.④86.96 percent of the major clinical manifestation are muscular soreness,hypodynamia and tumidness in DTC patients undergoing a four-week levothyroxine withdrawal.Conclusions ① Levothyroxine withdrawal can lead to abnormal AST,LDH,CK,TG,TC,HDL,and LDL levels.② The changes in the serum creatase enzymes and lipids of patients with DTC withdrawal were reversible.③ The FT3 and FT4 levels influenced CK abnormality.④Hypothyroid myopathy occurred in DTC patients undergoing a four-week levothyroxine withdrawal,and the clinical manifestation was improved by reusing levothyroxine.

参考文献/References:

[1] Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions[J]. Endocr Rev 2010, 31(2):139-170. DOI:10.1210/er.2009-0007.
[2] 仲崇翔, 王东, 廖日洪. 血清肌酶谱变化与运动性横纹肌溶解症的关系[J].中国实用医刊, 2011, 38(23):74-75. DOI:10.3760/cma. j.issn.1674-4756.2011.23.033. Zhong CX, Wang D, Liao RH. The change of serum creatase enzymes and exertional rhabdomyolysis[J]. Chin J Pract Med, 2011, 38(23):74-75.
[3] Hekimsoy Z, Oktem IK. Serum creatine kinase levels in overt and subclinical hypothyroidism[J]. Endocr Res, 2005, 31(3):171-175.
[4] Benavides VC, Rivkees SA. Myopathy associated with acute hypo-thyroidism following radioiodine therapy for Graves disease in an adolescent[J/OL]. Int J Ped Endocrinol, 2010, 2010:717303[2017-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943113/. DOI:10.1155/2010/717303.
[5] Duntas LH.Thyroid disease and lipids[J]. Thyroid, 2002, 12(4):287-293. DOI:10.1089/10507250252949405.
[6] 陆再英, 钟南山, 谢毅, 等. 内科学[M]. 7版. 人民卫生出版社, 2008:267. Lu ZY, Zhong NS, Xie Y, et al. Internal Medicine[M]. 7th edition. People’s Health Publisher, 2008:267.
[7] Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease[J]. Endocrine, 2004, 24(1):1-13. DOI:10.1385/ENDO:24:1:001.
[8] Dudka J, Mandziuk S, Madej-Czerwonka B, et al. Effect of iodothyronine hormone status on doxorubicin related cardiotoxicity[J]. Folia Morphol (Warsz), 2013, 72(4):340-348.
[9] Chrisoulidou A, Pazaitou-Panayiotou K, Kaprara A, et al. Effects of thyroxine withdrawal in biochemical parameters and cardiac function and structure in patients with differentiated thyroid cancer[J]. Minerva Endocrinol, 2006, 31(2):173-178.
[10] Regalbuto C, Alagona C, Maiorana R, et al. Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer[J]. J Endocrinol Invest, 2006, 29(1):32-40.
[11] 李大年, 耿晓华. 甲状腺功能减退与神经肌肉损害[J]. 临床神经病学杂志, 2009, 22(1):70-72. DOI:1004-1648(2009)01-0070-03. Li DN, Geng XH. Hypothyroidism with neuromuscular lesion[J]. J Clin Neurol, 2009, 22(1):70-72.
[12] Sindoni A, Rodolico C, Pappalardo MA, et al. Hypothyroid myopathy:A peculiar clinical presentation of thyroid failure[J]. Rev Endocr Metab Disord, 2016:17(4):499-519. DOI:10.1007/s11154-016-9357-0.
[13] 马志宇, 苏靖翠, 佟淼, 等. 124例横纹肌溶解征诊治体会[J]. 中国医科大学学报, 2013, 42(10):953-954. DOI:0258-4646(2013)10-0953-02. Ma ZY, Su JC, Tong M, et al. Experience of diagnosis and treatment in 124 cases of rhabdomyolysis[J]. J China Med Univ, 2013, 42(10):953-954.
[14] 陈志涵, 林禾, 高飞. 甲状腺功能减退性肌病18例临床分析[J]. 疑难病杂志, 2012, 11(10):788-789. DOI:10.3969/j.issn.1671-6450.2012.10.024. Chen ZH, Lin H, Gao F. Clinical analysis of 18 cases of hypothyroid myopathy[J]. J Diffic Complicat Case, 2012, 11(10):788-789.
[15] 王梅, 张莉芸, 李小峰, 等.甲状腺功能减退性肌病误诊3例并文献复习[J]. 中华临床免疫和变态反应杂志, 2012, 6(2):121-124. DOI:1673-8705(2012)02-0121-04. Wang M, Zhang LY, Li XF, et al. Three cases of misdiagnosed hypothyroid myopathy[J]. Chin J Allergy Clin Immunol, 2012, 6(2):121-124.
[16] 江敏华, 吴桂珍, 张勇辉, 等.以肌酸激酶异常升高为突出表现的甲状腺功能减退症13例误诊分析[J]. 中华保健医学杂志, 2012, 14(5):116-117. DOI:10.3969/j.issn.1674-3245.2012.05.028. Jiang MH, Wu GZ, Zhang YH, et al. Thirteen Cases of Misdiagnosed hypothyroidism with high creatine kinase[J]. Chin J Health Care Med, 2012, 14(5):116-117.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
 Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
 yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
 Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
 Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
 Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
 Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
 Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
 Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
 Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]

备注/Memo

备注/Memo:
收稿日期:2017-01-05。
通讯作者:徐颖,Email:Xy806nuclide@126.com
更新日期/Last Update: 2017-07-31